Researchers at Osaka University have uncovered a breakthrough that could reshape our understanding of aging. Their latest study reveals that specific cellular proteins, along with a common diabetes medication, may help slow cellular aging and even reverse age-related decline at a microscopic level. This discovery opens a hopeful road toward longer, healthier lives.
As the years pass, the body’s cells begin to lose their strength and precision. A key driver of this decline is cellular senescence a condition where cells stop dividing yet refuse to die, lingering like silent shadows. These so-called “zombie cells” release harmful molecules that damage surrounding tissue. With time, their buildup fuels serious conditions such as heart disease, diabetes, Alzheimer’s, and even cancer.
While aging is a natural process, scientists have long searched for ways to manage or reverse the harmful effects of cellular senescence. Researchers at Osaka University have now identified molecules that play a role in this process, offering new hope for anti-aging therapies.
The most exciting discoveries involves a protein called AP2A1. This protein helps regulate a process known as clathrin-mediated endocytosis, which acts like a delivery system inside cells, allowing nutrients and molecules to move in and out.
However, researchers found that as cells age, AP2A1 levels and activity change, disrupting the cell’s structure and movement. When scientists reduced AP2A1 in aged cells, many signs of aging were reversed the cells began to behave like young, healthy ones again.
This shows that AP2A1 might be a regulator of the aging process at the cellular level. Targeting this protein could someday help slow aging or repair damaged tissues in humans.
Another compound at the center of the study isIU1, a drug known to inhibit the enzyme USP14, which helps cells remove damaged proteins. By blocking USP14, IU1 activates two major cellular cleanup systems: proteasomes and autophagy.
Proteasomes destroy misfolded proteins, while autophagy recycles old or damaged components. Together, these systems keep cells clean and functional. IU1’s ability to boost both simultaneously could reduce age-related weakness and extend lifespan at least in lab models.
In another study led by Japanese researcher Katsuumi and colleagues, the team found that canagliflozin (Cana) an FDA-approved drug used to treat type 2 diabetes may have senolytic properties, meaning it helps remove harmful senescent cells.
Also Read: HIV Treatment Now Comparable to Chronic Conditions Like Diabetes
When tested on obese mice fed a high-fat diet, Cana reduced the number of senescent cells and inflammation in just one week. The drug activates AMPK, an enzyme linked to longevity and energy regulation, which helps the body eliminate aged or damaged cells that the immune system fails to remove.
AMPK is also activated naturally during fasting or low-sugar conditions, which explains why limiting calorie or carbohydrate intake has been associated with slower aging and improved metabolic health.
Beyond its role in helping slow cellular aging, canagliflozin also demonstrated strong protective effects against heart disease. In mouse studies focused on atherosclerosis, a condition marked by fatty buildup that narrows the arteries, the drug noticeably reduced both plaque accumulation and inflammation in the aorta, the body’s largest and most vital artery.
Even more impressively, when tested on mice with Hutchinson–Gilford progeria syndrome, a rare condition that causes premature aging, canagliflozin extended lifespan and improved physical strength. While results in naturally aged mice were less dramatic, the improvement in muscle function and balance show the drug’s potential to enhance quality of life in older individuals.
The researchers also explored whether dietary changes could achieve similar anti-aging effects. Since canagliflozin works by lowering blood glucose and activating AMPK, reducing sugar and carbohydrate intake could trigger the same mechanism naturally.
Diets like the ketogenic or low-carb diet, known for lowering blood glucose and stimulating AMPK, have already shown promise in animal studies for extending lifespan and reducing inflammation. However, researchers caution that more human studies are needed to determine the right balance and long-term effects.
